LETI & CELLMIC LLC To accelerate the global market adoption of lens-free diagnostics and biomedical sensing

GRENOBLE, France & LOS ANGELES – May 3, 2018 – Leti, a research institute at CEA Tech, and Cellmic LLC, a company dedicated to improving patient healthcare with smartphones and biophotonics, today announced that they joined forces to accelerate the market adoption of lens-free imaging and sensing techniques by growing Leti’s patent portfolio with a core patent from Cellmic.

Pioneered by Aydogan Ozcan, UCLA’s chancellor’s professor, and his research group, this patented computational lens-free imaging approach reconstructs detailed images of specimens from their holographic shadows that contain unique 3D information of samples, such as tissue sections, blood smears and cell cultures. Cellmic LLC, a UCLA spin-off, holds some of the core patents of this important computational imaging technique.

Lens-free microscopy has emerged as a powerful imaging and sensing platform that replaces bulky and expensive optical components that are found in standard optical microscopy systems with dedicated algorithms. Leti developed a lens-free microscope in 2012. Today the technology offers an ultra-wide field-of-view, tracking more than 10,000 biological, microscopic objects at a time per image, providing lab techs with a cost-effective, highly compact and robust solution. The Cellmic patent complements Leti’s IP portfolio and accelerates its ongoing valorization of its lens-free technology for diagnostics, biomedical sensing and related applications.

“Lens-free, on-chip imaging offers a very unique opportunity to bring advanced microscopy and sensing tools into your pocket with a fraction of the cost of existing technologies,” said Ozcan, who is also a co-founder of Cellmic LLC. “We are proud to have made fundamental contributions to establish this technique, which has been benefiting researchers in both academia and industry at a global scale.”

“Our partnership with Leti will help this powerful imaging and sensing technology to reach different markets through Leti’s powerful collaborations with other companies in various industries,” added Neven Karlovac, the CEO and co-founder of Cellmic LLC.

“Ozcan’s research lab and Cellmic have done ground-breaking work in developing lens-free imaging techniques,” said Jean-Marc Dinten, Leti Imaging department manager and international expert. “This core patent complements our lens-free technology development, such as point-of-care diagnosis for spinal meningitis.”

About Leti

Leti, a technology research institute at CEA Tech, is a global leader in miniaturization technologies enabling smart, energy-efficient and secure solutions for industry. Founded in 1967, Leti pioneers micro-& nanotechnologies, tailoring differentiating applicative solutions for global companies, SMEs and startups. Leti tackles critical challenges in healthcare, energy and digital migration. From sensors to data processing and computing solutions, Leti’s multidisciplinary teams deliver solid expertise, leveraging world-class pre-industrialization facilities. With a staff of more than 1,900, a portfolio of 2,700 patents, 91,500 sq. ft. of cleanroom space and a clear IP policy, the institute is based in Grenoble, France, and has offices in Silicon Valley and Tokyo. Leti has launched 60 startups and is a member of the Carnot Institutes network. Follow us on www.leti-cea.com and @CEA_Leti.

CEA Tech is the technology research branch of the French Alternative Energies and Atomic Energy Commission (CEA), a key player in innovative R&D, defence & security, nuclear energy, technological research for industry and fundamental science, identified by Thomson Reuters as the second most innovative research organization in the world. CEA Tech leverages a unique innovation-driven culture and unrivalled expertise to develop and disseminate new

About Cellmic LLC

Cellmic, LLC is a technology company located in Los Angeles, California, and dedicated to improving patient healthcare with the use of smartphones and bio-photonics.  The company is a licensee of UCLA and collaborates closely with Professor Aydogan Ozcan and his research group at the university.  Cellmic’s current products in use around the globe are a suite of rapid diagnostic test readers for lateral flow immunoassays including high-performance chromatographic, calorimetric, and fluorescent readers, as well as test development tools and cloud services. Main applications are in medical and veterinary point-of-care diagnostics, drugs-of abuse testing, food and crop testing, and bio-defenses.  The company continues its R&D for lens free holographic microscopes and handheld analyzers for a variety of applications. Cellmic holds the ISO 13485, FDA and the CE Mark registrations as a Medical Device Manufacturer.  The company was awarded Technology Pioneer 2015 by the World Economic Forum and was a finalist for the Katerva, Nokia Sensing X-Challenge, and SPIE PRISM awards, and has won numerous government and corporate research contracts.  For more information see www.cellmic.com and www.rapidassayreaders.com.